Nisa Investment Advisors
HRTX icon

Nisa Investment Advisors’s Heron Therapeutics HRTX Stock Holding History

Nisa Investment Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$141 Buy
+331
New +$265 ﹤0.01% 3058
2025
Q3 		– Sell
-1,456
Closed -$3.01K – 3030
2025
Q2 		$3.01K Buy
1,456
+400
+38% +$817 ﹤0.01% 2528
2025
Q1 		$2.32K Buy
1,056
+956
+956% +$1.85K ﹤0.01% 2430
2024
Q4 		$153 Sell
100
-106
-51% -$172 ﹤0.01% 2968
2024
Q3 		$410 Sell
206
-93
-31% -$222 ﹤0.01% 2756
2024
Q2 		$1.05K Buy
299
+135
+82% +$415 ﹤0.01% 2507
2024
Q1 		$454 Buy
164
+64
+64% +$161 ﹤0.01% 2515
2023
Q4 		$170 Sell
100
-985
-91% -$1.08K ﹤0.01% 2578
2023
Q3 		$1.12K Hold
1,085
– – ﹤0.01% 2384
2023
Q2 		$1.26K Sell
1,085
-100
-8% -$178 ﹤0.01% 2404
2023
Q1 		$2K Buy
1,185
+33
+3% +$83 ﹤0.01% 2322
2022
Q4 		$3K Buy
1,152
+67
+6% +$216 ﹤0.01% 2338
2022
Q3 		$4K Hold
1,085
– – ﹤0.01% 2319
2022
Q2 		$3K Sell
1,085
-56,200
-98% -$226K ﹤0.01% 2318
2022
Q1 		$328K Buy
57,285
+56,200
+5,180% +$411K ﹤0.01% 1204
2021
Q4 		$9K Sell
1,085
-8,704
-89% -$88.9K ﹤0.01% 2041
2021
Q3 		$105K Buy
9,789
+4,604
+89% +$56.1K ﹤0.01% 1675
2021
Q2 		$80K Hold
5,185
– – ﹤0.01% 1800
2021
Q1 		$84K Hold
5,185
– – ﹤0.01% 1822
2020
Q4 		$110K Buy
5,185
+950
+22% +$16.5K ﹤0.01% 1695
2020
Q3 		$63K Buy
4,235
+3,400
+407% +$53K ﹤0.01% 1711
2020
Q2 		$12K Buy
835
+95
+13% +$1.56K ﹤0.01% 1882
2020
Q1 		$9K Buy
740
+270
+57% +$5.08K ﹤0.01% 1866
2019
Q4 		$11K Hold
470
– – ﹤0.01% 1808
2019
Q3 		$9K Buy
470
+160
+52% +$2.94K ﹤0.01% 1807
2019
Q2 		$6K Hold
310
– – ﹤0.01% 1862
2019
Q1 		$8K Hold
310
– – ﹤0.01% 1819
2018
Q4 		$8K Hold
310
– – ﹤0.01% 1700
2018
Q3 		$10K Buy
+310
New +$11.5K ﹤0.01% 1728

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Nisa Investment Advisors's HRTX Position: Q2 2026 in Review

Nisa Investment Advisors opened a new position in Heron Therapeutics (HRTX) in Q2 2026: 331 shares worth $141. The stake represents ﹤0.01% of the portfolio and ranks #3058 among its holdings. This is a return to the name: Nisa Investment Advisors previously reported a position in HRTX as recently as Q2 2025.

Nisa Investment Advisors first reported a position in HRTX in Q3 2018 and has held it in 29 quarters since. The position peaked at $328K in Q1 2022. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Nisa Investment Advisors held 331 shares of Heron Therapeutics worth $141 as of Q2 2026.
  • Heron Therapeutics was a new Nisa Investment Advisors position in Q2 2026.
  • Heron Therapeutics made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q2 2026, its #3058 holding.
  • Nisa Investment Advisors first reported a position in Heron Therapeutics in Q3 2018 and has held it in 29 quarters since.
  • Nisa Investment Advisors's Heron Therapeutics position peaked at $328K in Q1 2022.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Nisa Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.